Most drugs summarized in the following paragraphs are already used in the management of some oncological diseases, such as PD-L1 inhibitors (Pembrolizumab) that represent the first-line monotherapy for advanced non-small cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations, based on the results of the phase III trial KEYNOTE 024 [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.